Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Inclusion Criteria: * Infant greater than 48 hours of life after birth up to day of life 120 at the time of culture acquisition * Diagnosis of proven invasive candidiasis within 4 days prior to study start * Subject's parent or legal guardian agrees not to allow subject to participate in another study with another investigational drug while on treatment. Exclusion Criteria: * Infant with any history of a hypersensitivity or severe vasomotor reaction to any echinocandin or systemic amphotericin B product * Infant who has received more than 48 hours of systemic antifungal therapy prior to the first dose of study drug * Infant who has a breakthrough systemic fungal infection while receiving amphotericin B product or an echinocandin as prophylaxis * Infant who has failed prior systemic antifungal therapy for this episode of invasive candidiasis * Infant who is co-infected with a non-Candida fungal organism * Infant whose positive yeast cultures are solely from an indwelling bladder catheter (unless obtained at the time the indwelling catheter was placed) or sputum. * Infant previously enrolled in this study